Alkermes Plc (ALKS) live share price

Alkermes Plc share price in USD $29.02 & INR ₹2,457.85

$29.02

▲

-0.3

(-1.02%)

View live Alkermes Plc share price in Dollar and Rupees. Guide to invest in Alkermes Plc from India. Also see the sentimental analysis on Indian investors investing in Alkermes Plc. Get details on the Indian mutual funds that are investing in Alkermes Plc. Get Analyst recommendations and forecasts along with all the Alkermes Plc's financials.

Alkermes Plc share price movements

$28.90
$29.31
$29.02
0.41%
Downside
Day's Volatility :1.4%
Upside
0.99%
$22.90
$32.88
$29.02
21.09%
Downside
52 Weeks Volatility :30.35%
Upside
11.74%

Alkermes Plc Returns

Period	Alkermes Plc	Sector (Health Care)	Index (Russel 2000)
3 Months	3.2%	-6.2%	0.0%
6 Months	20.64%	2.6%	0.0%
1 Year	10.22%	11.8%	0.0%
3 Years	31.67%	13.3%	-19.8%

Alkermes Plc Key Statistics

in dollars & INR

Market Capitalization	$4.7B
Revenue TTM	$1.5B
EBITDA	$358.8M
Earnings Per Share (EPS)	$2.29
PE Ratio	12.8
Profit Margin	22.15%
Quarterly Earnings Growth YOY	1.03%
Return On Equity TTM	29.23%

How to invest in Alkermes Plc from India?

It is very easy for Indian residents to invest directly in Alkermes Plc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Alkermes Plc stock in both rupees (INR) and dollars (USD). Search for Alkermes Plc or ALKS on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Alkermes Plc or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Alkermes Plc shares which would translate to 0.029 fractional shares of Alkermes Plc as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Alkermes Plc

50%

Period: Sep 2, 2024 to Dec 1, 2024. Change in 30 Days versus previous period

Search volume for Alkermes Plc on INDmoney from India has grown in the last 30 days as on Dec 2, 2024. 50% more investors are searching Alkermes Plc in the last 30 days versus the previous period.

Global Institutional Holdings in Alkermes Plc

BlackRock Inc
17.99%
Vanguard Group Inc
11.73%
Wellington Management Company LLP
8.87%
T. Rowe Price Associates, Inc.
6.81%
State Street Corp
5.70%
RTW INVESTMENTS, LLC
4.36%

Analyst Recommendation on Alkermes Plc

Buy

63%Buy

31%Hold

5%Sell

Based on 19 Wall street analysts offering stock ratings for Alkermes Plc(by analysts ranked 0 to 5 stars)

Based on 19 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Alkermes Plc

What analysts predicted

Upside of 17.43%

Current:

$29.02

Target:

$34.08

Insights on Alkermes Plc

Decreasing Revenue
Revenue is down for the last 2 quarters, 399.13M → 378.14M (in $), with an average decrease of 5.3% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, 36.82M → 92.38M (in $), with an average increase of 30.4% per quarter
Vs CTLT
In the last 1 year, Catalent, Inc. has given 52.2% return, outperforming this stock by 32.7%

Alkermes Plc Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$1.1B	↑ 21.13%
Net Income	$-139.3M	↓ 11.8%
Net Profit Margin	-12.73%	↑ 4.75%

	FY19	Y/Y Change
Revenue	$1.2B	↑ 7.01%
Net Income	$-196.6M	↑ 41.14%
Net Profit Margin	-16.79%	↓ 4.06%

	FY20	Y/Y Change
Revenue	$1.0B	↓ 11.29%
Net Income	$-110.9M	↓ 43.62%
Net Profit Margin	-10.67%	↑ 6.12%

	FY21	Y/Y Change
Revenue	$1.2B	↑ 13.0%
Net Income	$-48.2M	↓ 56.55%
Net Profit Margin	-4.1%	↑ 6.57%

	FY22	Y/Y Change
Revenue	$1.1B	↓ 5.28%
Net Income	$-158.3M	↑ 228.57%
Net Profit Margin	-14.24%	↓ 10.14%

	FY23	Y/Y Change
Revenue	$1.7B	↑ 49.61%
Net Income	$355.8M	↓ 324.78%
Net Profit Margin	21.39%	↑ 35.63%

	Q2 FY23	Q/Q Change
Revenue	$617.4M	↑ 114.68%
Net Income	$237.1M	↓ 666.53%
Net Profit Margin	38.4%	↑ 52.95%

	Q3 FY23	Q/Q Change
Revenue	$380.9M	↓ 38.3%
Net Income	$47.8M	↓ 79.85%
Net Profit Margin	12.54%	↓ 25.86%

	Q4 FY23	Q/Q Change
Revenue	$377.5M	↓ 0.91%
Net Income	$112.8M	↑ 136.15%
Net Profit Margin	29.88%	↑ 17.34%

	Q1 FY24	Q/Q Change
Revenue	$350.4M	↓ 7.18%
Net Income	$36.8M	↓ 67.34%
Net Profit Margin	10.51%	↓ 19.37%

	Q2 FY24	Q/Q Change
Revenue	$399.1M	↑ 13.92%
Net Income	$91.4M	↑ 148.07%
Net Profit Margin	22.89%	↑ 12.38%

	Q3 FY24	Q/Q Change
Revenue	$378.1M	↓ 5.26%
Net Income	$92.4M	↑ 1.12%
Net Profit Margin	24.43%	↑ 1.54%

	FY18	Y/Y Change
Total Assets	$1.8B	↑ 1.55%
Total Liabilities	$653.7M	↑ 9.98%

	FY19	Y/Y Change
Total Assets	$1.8B	↓ 1.07%
Total Liabilities	$720.0M	↑ 10.13%

	FY20	Y/Y Change
Total Assets	$1.9B	↑ 7.99%
Total Liabilities	$882.7M	↑ 22.61%

	FY21	Y/Y Change
Total Assets	$2.0B	↑ 3.83%
Total Liabilities	$911.9M	↑ 3.3%

	FY22	Y/Y Change
Total Assets	$2.0B	↓ 2.99%
Total Liabilities	$920.2M	↑ 0.91%

	FY23	Y/Y Change
Total Assets	$2.1B	↑ 8.77%
Total Liabilities	$933.5M	↑ 1.45%

	Q2 FY23	Q/Q Change
Total Assets	$2.2B	↑ 13.75%
Total Liabilities	$906.7M	↓ 1.13%

	Q3 FY23	Q/Q Change
Total Assets	$2.3B	↑ 4.21%
Total Liabilities	$923.6M	↑ 1.86%

	Q4 FY23	Q/Q Change
Total Assets	$2.1B	↓ 6.27%
Total Liabilities	$933.5M	↑ 1.07%

	Q1 FY24	Q/Q Change
Total Assets	$2.1B	↓ 0.58%
Total Liabilities	$869.1M	↓ 6.9%

	Q2 FY24	Q/Q Change
Total Assets	$2.2B	↑ 3.91%
Total Liabilities	$922.8M	↑ 6.18%

	Q3 FY24	Q/Q Change
Total Assets	$2.2B	↓ 2.34%
Total Liabilities	$863.2M	↓ 6.46%

	FY18	Y/Y Change
Operating Cash Flow	$99.3M	↑ 417.36%
Investing Cash Flow	$-22.2M	↑ 20.91%
Financing Cash Flow	$-1.6M	↓ 139.67%

	FY19	Y/Y Change
Operating Cash Flow	$72.1M	↓ 27.4%
Investing Cash Flow	$-141.8M	↑ 539.03%
Financing Cash Flow	$6.8M	↓ 517.59%

	FY20	Y/Y Change
Operating Cash Flow	$82.8M	↑ 14.94%
Investing Cash Flow	$-11.5M	↓ 91.91%
Financing Cash Flow	$-2.2M	↓ 132.09%

	FY21	Y/Y Change
Operating Cash Flow	$101.7M	↑ 22.78%
Investing Cash Flow	$-66.2M	↑ 476.64%
Financing Cash Flow	$29.1M	↓ 1439.11%

	FY22	Y/Y Change
Operating Cash Flow	$21.0M	↓ 79.31%
Investing Cash Flow	$-64.5M	↓ 2.51%
Financing Cash Flow	$-1.6M	↓ 105.41%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$215.7M	↓ 1112.63%
Investing Cash Flow	$-119.4M	↓ 263.84%
Financing Cash Flow	$7.8M	↓ 134.64%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$99.7M	↓ 53.78%
Investing Cash Flow	$-119.4M	↑ 0.0%
Financing Cash Flow	$1.6M	↓ 80.0%

Alkermes Plc Technicals Summary

Sell

Neutral

Buy

Alkermes Plc is currently in a neutral trading position according to technical analysis indicators.

Alkermes Plc Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Alkermes Plc	9.14%	20.64%	10.22%	31.67%	36.69%
Neurocrine Biosciences Inc.	5.16%	-9.41%	8.77%	59.07%	6.9%
Haleon Plc Spon Ads	-1.02%	14.05%	14.05%	30.36%	30.36%
Zoetis Inc.	0.04%	1.67%	-3.77%	-21.53%	46.36%
Viatris Inc.	14.32%	23.72%	35.23%	7.3%	-19.89%
Catalent, Inc.	4.12%	12.58%	52.89%	-50.1%	18.02%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Alkermes Plc	12.8	12.8	-1057.29	2.6	0.29	0.09	NA	7.99
Neurocrine Biosciences Inc.	33.76	33.76	0.3	6.54	0.16	0.12	NA	26.87
Haleon Plc Spon Ads	29.45	29.45	1.75	0.34	0.07	0.04	0.02	1.82
Zoetis Inc.	33.22	33.22	2.46	5.87	0.47	0.15	0.01	11.59
Viatris Inc.	224.4	NA	0.08	2.67	-0.04	0.02	0.04	16.58
Catalent, Inc.	211.02	NA	508.33	0.2	-0.11	0.0	NA	19.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Alkermes Plc	Buy	$4.7B	36.69%	12.8	22.15%
Neurocrine Biosciences Inc.	Buy	$12.8B	6.9%	33.76	17.21%
Haleon Plc Spon Ads	Buy	$43.9B	30.36%	29.45	10.75%
Zoetis Inc.	Buy	$79.7B	46.36%	33.22	26.55%
Viatris Inc.	Hold	$15.1B	-19.89%	224.4	-5.87%
Catalent, Inc.	Hold	$11.1B	18.02%	211.02	-9.34%

About Alkermes Plc

alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.

Organization	Alkermes Plc
Employees	2100
CEO	Mr. Richard F. Pops
Industry	Health Technology

Important FAQs about investing in Alkermes Plc from India :

What is Alkermes Plc share price today?

Alkermes Plc (ALKS) share price today is $29.02.

Can Indians buy Alkermes Plc shares?

Yes, Indians can invest in the Alkermes Plc (ALKS) from India.

With INDmoney, you can buy Alkermes Plc at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Alkermes Plc at zero transaction cost.

How can I buy Alkermes Plc shares from India?

It is very easy to buy Alkermes Plc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Alkermes Plc be purchased?

Yes, you can buy fractional shares of Alkermes Plc with INDmoney app.

What are the documents required to start investing in Alkermes Plc stocks?

To start investing in Alkermes Plc, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.